(GRFS) Grifols - Ratings and Ratios
Immunoglobulin, Albumin, Clotting-Factors, Alpha-1, Diagnostic
| Risk via 10d forecast | |
|---|---|
| Volatility | 50.8% |
| Value at Risk 5%th | 69.0% |
| Relative Tail Risk | -17.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.14 |
| Alpha | -19.06 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.374 |
| Beta | 0.965 |
| Beta Downside | 1.018 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.68% |
| Mean DD | 23.57% |
| Median DD | 24.08% |
Description: GRFS Grifols November 04, 2025
Grifols S.A. (NASDAQ: GRFS) is a global plasma-derived therapeutics company headquartered in Barcelona, operating across Spain, the United States, Canada and other markets. Its product portfolio spans immunoglobulins for primary immunodeficiency, albumin for volume replacement, Alpha-1 Proteinase Inhibitor for hereditary deficiency, clotting factors (FVIII/VWF, FIX) for hemophilia, antithrombin III, the spleen-tyrosine-kinase inhibitor Fostamatinib, surgical sealants (VISTASEAL), and plasma-exchange therapies targeting Alzheimer’s disease. Grifols also supplies diagnostic reagents, manufactures plasma for third-party customers, and advances a pipeline that includes Yimmugo (immunology/hematology), Prolastin-C (pulmonology), and several pre-clinical candidates (e.g., GRF6019, AKST4290, GIGA-564).
Key quantitative indicators (FY 2023) show ≈ $2.6 billion in total revenue, with plasma-derived products contributing roughly 70 % and a net cash position of $1.1 billion, reflecting strong cash generation from its vertically integrated model. The company collected about 12 million liters of plasma in 2023, positioning it among the top three global plasma collectors-a critical driver given the aging-population trend that is expanding demand for plasma-based therapies at an estimated CAGR of 6-7 % through 2030. Regulatory risk remains material; the FDA’s ongoing scrutiny of plasma-manufacturing practices can materially affect operating margins, while the European Union’s push for self-sufficiency in plasma products creates both a head-wind for export-oriented firms and a potential growth avenue in domestic contracts.
For a deeper quantitative assessment, you may explore the detailed valuation metrics and peer comparisons on ValueRay.
GRFS Stock Overview
| Market Cap in USD | 7,645m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2006-05-17 |
| Return 12m vs S&P 500 | -10.9% |
| Analyst Rating | 4.0 of 5 |
GRFS Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 2.05% |
| Yield on Cost 5y | 0.97% |
| Yield CAGR 5y | 126.87% |
| Payout Consistency | 60.7% |
| Payout Ratio | 27.1% |
GRFS Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 1.62% |
| CAGR/Max DD Calmar Ratio | 0.03 |
| CAGR/Mean DD Pain Ratio | 0.07 |
| Current Volume | 622.8k |
| Average Volume | 600.3k |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (372.7m TTM) > 0 and > 6% of Revenue (6% = 451.1m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 2.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 42.48% (prev 42.36%; Δ 0.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 1.13b > Net Income 372.7m (YES >=105%, WARN >=100%) |
| Net Debt (456.0m) to EBITDA (1.55b) ratio: 0.30 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.48 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (680.5m) change vs 12m ago 0.13% (target <= -2.0% for YES) |
| Gross Margin 39.46% (prev 39.04%; Δ 0.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 37.46% (prev 34.54%; Δ 2.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.58 (EBITDA TTM 1.55b / Interest Expense TTM 467.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.87
| (A) 0.16 = (Total Current Assets 5.35b - Total Current Liabilities 2.15b) / Total Assets 19.85b |
| (B) 0.01 = Retained Earnings (Balance) 201.7m / Total Assets 19.85b |
| (C) 0.06 = EBIT TTM 1.21b / Avg Total Assets 20.07b |
| (D) 0.36 = Book Value of Equity 4.40b / Total Liabilities 12.31b |
| Total Rating: 1.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.94
| 1. Piotroski 5.0pt |
| 2. FCF Yield 12.36% |
| 3. FCF Margin 11.32% |
| 4. Debt/Equity 0.21 |
| 5. Debt/Ebitda 0.30 |
| 6. ROIC - WACC (= -3.40)% |
| 7. RoE 6.82% |
| 8. Rev. Trend 76.48% |
| 9. EPS Trend 63.04% |
What is the price of GRFS shares?
Over the past week, the price has changed by -3.10%, over one month by -11.91%, over three months by -16.95% and over the past year by -0.35%.
Is GRFS a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GRFS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.5 | 48.6% |
| Analysts Target Price | 12.5 | 48.6% |
| ValueRay Target Price | 8.8 | 3.8% |
GRFS Fundamental Data Overview November 16, 2025
P/E Trailing = 13.8095
P/E Forward = 9.7371
P/S = 1.0157
P/B = 0.9851
P/EG = 0.229
Beta = 1.19
Revenue TTM = 7.52b EUR
EBIT TTM = 1.21b EUR
EBITDA TTM = 1.55b EUR
Long Term Debt = 8.42b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 111.0m EUR (from shortTermDebt, last quarter)
Debt = 1.08b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 456.0m EUR (from netDebt column, last quarter)
Enterprise Value = 6.89b EUR (6.64b + Debt 1.08b - CCE 825.5m)
Interest Coverage Ratio = 2.58 (Ebit TTM 1.21b / Interest Expense TTM 467.0m)
FCF Yield = 12.36% (FCF TTM 851.2m / Enterprise Value 6.89b)
FCF Margin = 11.32% (FCF TTM 851.2m / Revenue TTM 7.52b)
Net Margin = 4.96% (Net Income TTM 372.7m / Revenue TTM 7.52b)
Gross Margin = 39.46% ((Revenue TTM 7.52b - Cost of Revenue TTM 4.55b) / Revenue TTM)
Gross Margin QoQ = 40.29% (prev 39.33%)
Tobins Q-Ratio = 0.35 (Enterprise Value 6.89b / Total Assets 19.85b)
Interest Expense / Debt = 14.49% (Interest Expense 156.1m / Debt 1.08b)
Taxrate = 27.61% (54.7m / 198.1m)
NOPAT = 872.9m (EBIT 1.21b * (1 - 27.61%))
Current Ratio = 2.48 (Total Current Assets 5.35b / Total Current Liabilities 2.15b)
Debt / Equity = 0.21 (Debt 1.08b / totalStockholderEquity, last quarter 5.18b)
Debt / EBITDA = 0.30 (Net Debt 456.0m / EBITDA 1.55b)
Debt / FCF = 0.54 (Net Debt 456.0m / FCF TTM 851.2m)
Total Stockholder Equity = 5.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.88% (Net Income 372.7m / Total Assets 19.85b)
RoE = 6.82% (Net Income TTM 372.7m / Total Stockholder Equity 5.47b)
RoCE = 8.68% (EBIT 1.21b / Capital Employed (Equity 5.47b + L.T.Debt 8.42b))
RoIC = 6.30% (NOPAT 872.9m / Invested Capital 13.86b)
WACC = 9.70% (E(6.64b)/V(7.71b) * Re(9.57%) + D(1.08b)/V(7.71b) * Rd(14.49%) * (1-Tc(0.28)))
Discount Rate = 9.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.07%
[DCF Debug] Terminal Value 76.64% ; FCFE base≈625.9m ; Y1≈772.2m ; Y5≈1.32b
Fair Price DCF = 66.08 (DCF Value 17.06b / Shares Outstanding 258.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 63.04 | EPS CAGR: 56.14% | SUE: -0.59 | # QB: 0
Revenue Correlation: 76.48 | Revenue CAGR: 3.15% | SUE: 0.04 | # QB: 0
Additional Sources for GRFS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle